www.fdanews.com/articles/200914-chembio-earns-ce-mark-for-two-covid-19-tests
![](https://www.fdanews.com/ext/resources/test/Device_Images6/Chembio_Logo.gif?t=1576721381&width=430)
Chembio Earns CE Mark for Two COVID-19 Tests
January 19, 2021
New York-based Chembio has been granted CE mark certification for two COVID-19 tests, the DPP SARS-CoV-2 antigen and IgM/IgG tests.
The antigen test uses a test cartridge, a micro-reader analyzer and a nasal swab to detect coronavirus antigens in 20 minutes. The IgM/IgG test detects antibodies in the blood produced in response to COVID-19 infection. It generates results within 15 minutes using finger-stick, venous whole-blood, plasma or serum samples and a micro-reader analyzer.
The company has entered into a distribution agreement with Luas Diagnostics, which will begin sales of the tests immediately and serve as the exclusive commercial partner for Chembio products in the UK and Ireland.